Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accumulated Expenses (2020 - 2025)

Tarsus Pharmaceuticals has reported Accumulated Expenses over the past 6 years, most recently at $17.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $17.8 million for Q4 2025, up 12.36% from a year ago — trailing twelve months through Dec 2025 was $17.8 million (up 12.36% YoY), and the annual figure for FY2025 was $17.8 million, up 12.36%.
  • Accumulated Expenses for Q4 2025 was $17.8 million at Tarsus Pharmaceuticals, up from $13.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TARS hit a ceiling of $17.8 million in Q4 2025 and a floor of $685000.0 in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $5.7 million (2022), compared with a mean of $7.3 million.
  • Biggest five-year swings in Accumulated Expenses: soared 331.92% in 2021 and later grew 12.36% in 2025.
  • Tarsus Pharmaceuticals' Accumulated Expenses stood at $2.8 million in 2021, then surged by 97.25% to $5.5 million in 2022, then soared by 139.99% to $13.2 million in 2023, then grew by 19.46% to $15.8 million in 2024, then rose by 12.36% to $17.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $17.8 million (Q4 2025), $13.6 million (Q3 2025), and $11.6 million (Q2 2025) per Business Quant data.